- Home
- NTRB vs CLNN Comparison
NTRB vs CLNN Comparison
Compare NTRB & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTRB | CLNN |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | 3 | 79 |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.1M | 60.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NTRB | CLNN |
|---|---|---|
| Price | $3.54 | $5.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $32.67 |
| AVG Volume (30 Days) | 11.6K | ★ 77.6K |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.17 | $12.20 |
| Revenue Next Year | $3,394.36 | $20,465.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.42 | $2.28 |
| 52 Week High | $11.68 | $13.50 |
Technical Indicators
Market Signals| Indicator | NTRB | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 40.43 | 47.40 |
| Support Level | $3.53 | $3.54 |
| Resistance Level | $4.50 | $6.83 |
| Average True Range (ATR) | 0.29 | 0.62 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 27.27 | 29.26 |
Price Performance
Historical ComparisonAbout NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.